Product Description
Lactobacillus Kefiri LKF01 (DSM32079) to Colonize the Intestinal Environment and Modify the Gut Microbiota Composition of Newborns Born by Caesarian Section (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03154866)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Policlinico Hospital
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Stillbirth|Communicable Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03154866 |
KEFINEO1 | P4 |
Unknown status |
Communicable Diseases|Stillbirth |
2017-12-31 |
2019-05-03 |
Trial Status |
Recent News Events
Date |
Type |
Title |
|---|